Marc Lemonnier

Founding CEO of @antabio, a European biotech fighting #AMR; SAB member at @JPIAMR. Lead at ARPEGE_AMR

[Marc Lemonnier @MLantabio]

This is where I will be living, starting today
#Bluesky
#GoodbyeElon

[Valeria Gigante @valeria_gigante]

⚡️ Great panel on the value of antibiotics.
We need ABs able to address the highest unmet medical needs and strong translational teams.

@AMRActionFund @AllianceBEAM
#AMR

[The Biotech Newswire @BiotechNewswire]

ANTABIO Raises €25 million in Series B Financing. The financing will be used to support the clinical development of MEM-ANT3310, a next generation antibacterial combination currently in phase 1 trials https://t.co/0fsXnEpNfb #biotech

[CIDRAP @CIDRAP]

French drugmaker receives funding for combination antibiotic

Antabio announced that it raised $25 million in financing to complete phase 2 research on its antibiotic/beta-lactamase inhibitor combination.

https://t.co/N6Ns6svsCH

[AMR Action Fund @AMRActionFund]

We are thrilled to welcome @antabio to our portfolio. Learn more about the company's €25 million Series B round: https://t.co/bB1UGv3NhG #AMR

[La Tribune Toulouse @LaTribuneTlse]

#Toulouse - #Santé : Antabio boucle une série B majeure pour commercialiser son premier traitement https://t.co/q3NkOlmlIu via @LaTribuneTlse @LaTribune

[Maxime Le TEXIER // 🅜🅐🅧 @maxletex]

@capus_samuel @bleucitron_tour @Pictarine Intervention ensuite inspirante de Marc Lemonnier de @antabio sur une idée séduisante : faire un "Healthbus" toulousain en explorant un modèle multi partenarial public-privé comme sur ARPEGE
Complété dans le même sens par le directeur de @IUCTOncopole
autour du décloisonnement 8/

[Marc Lemonnier @MLantabio]

Très peiné par cette nouvelle. P-O G était toujours prêt à aider les biotechs françaises, toujours à l'écoute. Au nom d'@antabio, condoléances à sa famille et à ses proches.

[Hemarina @Hemarina]

Sous le choc du décès de Pierre-Olivier Goineau, j’adresse toutes mes condoléances à sa famille, ses proches et à ses amis. J’ai côtoyé plusieurs années POG au sein du CA de @FranceBiotech, c’était une belle personnalité, bienveillante et attachante, repose en paix POG. 🕊️

[Marc Lemonnier @MLantabio]

The start of our first in man study for MEM-ANT3310 marks a significant milestone for @antabio as we transition to becoming a clinical stage biotechnology company.
Today my warm gratitude goes to my colleagues at @antabio for their excellent work and continuous dedication.
#AMR

[@antabio @antabio]

@antabio announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310, a next generation treatment of hospital infections caused by carbapenem-resistant Acinetobacter baumannii (#CRAB) and carbapenem-resistant Enterobacterales (#CRE)
https://t.co/O3yqCDXNeu

[ESCMID @ESCMID]

Our first-place #ECCMID2023 Art Gallery winner is Ana Pelivan (Croatia) who won with her painting titled "Cause of Death" showcasing the fight against multidrug-resistant pathogens is difficult, and the most devastating feeling is losing a patient because of them. #ECCMIDart

[@antabio @antabio]

Check our new paper on the chemical optimization & initial evaluation in cellular & animal models of @antabio's #Pseudomonas #aeruginosa #LasB inhibitors.

An international collaboration based on a work initially funded by @wellcometrust & @CARB_X

https://t.co/YE76PnxRWA

[BEAM Alliance @AllianceBEAM]

3⃣Revenues from new antimicrobials do not recoup R&D investments.
As long as this equation is out of balance, it is impossible to have a fully functioning innovation engine.
➡️This is why a PULL mechanism should be of sufficient magnitude to bring things back into balance.

[BEAM Alliance @AllianceBEAM]

2⃣The biotech ecosystem is committed to developing new products, but #SMEs struggle to raise💰to fight #AMR
SMEs' survival is often measured in months which discourages talented👩‍🔬
⚠️Rapid action is urgently needed for a PULL mechanism to preserve this ecosystem and help it thrive

[Marc Lemonnier @MLantabio]

https://t.co/VkXkjDOSBa

[BEAM Alliance @AllianceBEAM]

Tomorrow kicks off #WAAW2022, so let's remember what's at stake. Next year will be critical in shaping tomorrow's innovation, with the #EU reshaping the pharmaceutical regulatory landscape. The future of #SMEs depends on it. Our future depends on it. https://t.co/P2fddmQoxo

[Marc Lemonnier @MLantabio]

A pivotal report from our partners at #ARPEGE @TSEinfo on how Transferable Exclusivity Vouchers can be an effective mechanism for rewarding innovation and revitalizing the #AMR market. 👇

[TSE @TSEinfo]

A new policy paper by Pierre Dubois, Paul-Henri Moisson & #JeanTirole focused on the mechanisms & levers to be used to encourage innovation in the #AntimicrobialResistance sector. #ARPEGE_AMR
👉 https://t.co/v0dkcTlHQr

[BEAM Alliance @AllianceBEAM]

BEAM signed a Call to Action to #G20 Leaders, Health and Finance Ministers. Take a look at the recommendations focusing on #AMR and help us spread the word to tackle AMR globally! https://t.co/rNyAxSGllM

[Marc Lemonnier @MLantabio]

@Christinerdal The honor and pleasure was mine! :-)

[BEAM Alliance @AllianceBEAM]

Great discussion today at the scientific symposium organized in the frame of the @Europe2022FR and dedicated to #antimicrobialresistance. The panel moderated by Marc Lemonnier and Christine Ardal showcased the options for incentivising innovation and what is at stake.

[BEAM Alliance @AllianceBEAM]

The #EU Pharma Legislation revision is on the horizon. What solutions do #SMEs need from our policymakers to unlock the innovation potential to tackle #AMR? Check out this video and don’t hesitate to spread the voice of SMEs too: like, share, and comment! https://t.co/h4SSOHkcWB